Ozempic and Wegovy's Active Ingredient May Slow Biological Aging

Researchers have found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV. The findings suggest that the drug may influence human aging, but larger studies are needed to confirm the results.
A recent study has shown that semaglutide, the active ingredient in the popular weight-loss drugs Ozempic and Wegovy, may have an effect on biological aging. The research found that semaglutide slowed biological aging markers in adults with HIV. This is the first clinical evidence that the drug may influence human aging. The study's findings are encouraging, but scientists are cautioning that larger studies are needed before any conclusions can be drawn about the medication's ability to help people age more slowly. The researchers are hopeful that their findings could lead to new avenues of research into the effects of semaglutide on aging. However, they also emphasize the need for further study to fully understand the potential benefits and risks of using the drug to slow biological aging. As the research continues to unfold, it may have significant implications for our understanding of the aging process and the development of new treatments to promote healthy aging.
The study's results are based on the analysis of biological aging markers in adults with HIV who were treated with semaglutide. The researchers used a variety of measures to assess biological aging, including epigenetic clocks and telomere length. They found that semaglutide slowed the pace of biological aging in these individuals, which could have important implications for their health and well-being. While the findings are promising, the researchers are careful to note that more research is needed to confirm the results and to understand the potential mechanisms by which semaglutide may influence biological aging.
Go Deeper
What are Ozempic and Wegovy?
Ozempic and Wegovy are popular weight-loss drugs that contain the active ingredient semaglutide. They are used to help people lose weight and improve their overall health.
What are biological aging markers?
Biological aging markers are measures used to assess the pace of aging in an individual. They can include epigenetic clocks, telomere length, and other indicators of biological age.
How did the researchers study the effect of semaglutide on biological aging?
The researchers studied the effect of semaglutide on biological aging by analyzing biological aging markers in adults with HIV who were treated with the drug. They used a variety of measures to assess biological aging, including epigenetic clocks and telomere length.
What are the implications of the study's findings?
The study's findings suggest that semaglutide may have an effect on biological aging, which could have important implications for our understanding of the aging process and the development of new treatments to promote healthy aging. However, more research is needed to confirm the results and to understand the potential mechanisms by which semaglutide may influence biological aging.
What's next for the research on semaglutide and biological aging?
The researchers are hopeful that their findings will lead to new avenues of research into the effects of semaglutide on aging. They plan to conduct larger studies to confirm the results and to understand the potential benefits and risks of using the drug to slow biological aging.
More health
An Experimental Alzheimer's Drug Showed Stronger Benefit at Two Years, but the Numbers Call for Caution
An experimental drug called diranersen showed hopeful two-year results in a study of people with early Alzheimer's disease, including about a 54 perce
Nov 21health50+Flu Is Spreading Early This Year, and Older Adults Face the Highest Risk
Flu is spreading unusually early this year, and adults 65 and older face the highest risk of being hospitalized. Doctors recommend a stronger flu shot
Nov 20health50+Medicare's Open Enrollment Ends December 7, and Some Costs Will Rise in 2027
Medicare's open enrollment ends December 7, and several costs, including the Part D out-of-pocket cap, are rising in 2027. There is still time to swit
Nov 20